German biotech CureVac's stock plunges 50% after its COVID-19 vaccine candidate failed a clinical trialBusiness Insider • 06/17/21
Coronavirus tally: Global cases of COVID-19 top 177 million and CureVac vaccine is just 47% effectiveMarket Watch • 06/17/21
CureVac shares tank 50% after preliminary data shows Covid vaccine is only 47% effectiveCNBC • 06/16/21
CureVac's COVID-19 shot just failed in a large trial, a major setback for the Gates-backed biotechBusiness Insider • 06/16/21
CureVac's Covid-19 Vaccine Has Important Role to Play in Fighting Variants, CEO SaysBarrons • 05/26/21
CureVac's COVID vaccine has important role to play in fighting variants, CEO saysMarket Watch • 05/26/21